Moshkevich Solomon sold $1.2M of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,000 shares of Natera, Inc. (NTRA) at an average of $414.22 ($411.62–$415.07, $1.24M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Oct 3, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale is modest in size and likely to have limited price effect, but traders may watch for any follow‑up activity.

02

Market read

Routine insider sale with limited immediate market impact; monitor for further insider activity or upcoming clinical trial news.

03

What to watch

Potential upcoming clinical data releases could outweigh the sell signal.

Relevance 5/10Novelty 4/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

President of Clinical Diagnostics sold 3,000 shares for $1.24M via a 10b5-1 plan.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $1.2M open‑market sale by a senior officer can be interpreted as a neutral to slightly bearish signal, but the amount is modest for a mid‑cap biotech.

Market effects

Minimal impact on the broader biotech sector.

None

Low

Counterpoint

The sale could be purely procedural under a 10b5‑1 plan and not reflect confidence.

Key entities

  • Natera, Inc.

    US‑listed genetic testing company (ticker NTRA).

  • Moshkevich Solomon

    President, Clinical Diagnostics at Natera.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.